Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
mRNA-1345 RSV vaccine trial in adults aged 60 years and older
2021-005026-20Phase 3Completed
- Sponsor
- Moderna Inc
- Start
- Mar 2022
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, single-blind trial in respiratory syncytial virus disease (RSV) comparing mRNA-1345 with Placebo (2 arms). Primary endpoint: Safety endpoint. Started Mar 2022; status: completed.
02
Drugs
RNA-100-AR02
03
Conditions
respiratory syncytial virus disease (RSV)
Beyond the preview
Go deeper on 2021-005026-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-005026-20.